PIK3CA and neoplasm: Caumanns et al. demonstrated the cooperative effects of AZD8055, GDC0941, and selumetinib, which are drugs with inhibitory action against mTORC1/2, PI3K, and MEK1/2, respectively, when co-administered at a low-dose in OCCCs both in vitro and in vivo, suggesting this triple drug combination as an effective treatment strategy for this tumor type [114].